Payment overview · 2025
General Payments
$314.18
17 reported records · 12 companies
Healthcare provider profile · identity verified
Gerald Anthony Sparks, MD
Allopathic & Osteopathic Physicians|Family Medicine · BAY MINETTE, AL · NPI 1770533507
Verified facts
What the public records show
CMS Open Payments records show Gerald Anthony Sparks, MD received $314.18 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.42 | 18.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.20 | 15.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.09 | 8.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.49 | 8.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.16 | 7.7% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $21.79 | 6.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.31 | 6.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.84 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.19 | 6.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.37 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.18 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.14 | 3.5% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.18 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 136 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 128 |
| Losartan Potassium | Losartan Potassium | 369 | 101 |
| Gabapentin | Gabapentin | 347 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 101 |
| Furosemide | Furosemide | 328 | 101 |
| Omeprazole | Omeprazole | 326 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 284 | 74 |
| Lisinopril | Lisinopril | 279 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 277 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 254 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 62 |
| Trazodone Hcl | Trazodone Hcl | 203 | 57 |
| Potassium Chloride | Potassium Chloride | 201 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 37 |
| Eliquis | Apixaban | 179 | 35 |
| Tramadol Hcl | Tramadol Hcl | 175 | 37 |
| Metformin Hcl Er | Metformin Hcl | 174 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 24 |
| Meloxicam | Meloxicam | 166 | 44 |
| Clonazepam | Clonazepam | 159 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 52 |
| Famotidine | Famotidine | 153 | 52 |
| Celecoxib | Celecoxib | 142 | 36 |
| Metformin Hcl | Metformin Hcl | 141 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 44 |
| Mounjaro | Tirzepatide | 136 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 41 |
| Simvastatin | Simvastatin | 127 | 38 |
| Glimepiride | Glimepiride | 118 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Sertraline Hcl | Sertraline Hcl | 115 | 27 |
| Carvedilol | Carvedilol | 112 | 39 |
| Buspirone Hcl | Buspirone Hcl | 108 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 29 |
| Alprazolam | Alprazolam | 103 | 15 |
| Ozempic | Semaglutide | 92 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 23 |
| Azithromycin | Azithromycin | 83 | 66 |
| Prednisone | Prednisone | 83 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 22 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 80 | 62 |
| Linzess | Linaclotide | 80 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 21 |
| Pregabalin | Pregabalin | 70 | 19 |
| Ezetimibe | Ezetimibe | 68 | 23 |
| Finasteride | Finasteride | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Mupirocin | Mupirocin | 67 | 38 |
| Allopurinol | Allopurinol | 63 | 21 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 63 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 60 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Trulicity | Dulaglutide | 54 | 14 |
| Donepezil Hcl | Donepezil Hcl | 53 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 15 |
| Meclizine Hcl | Meclizine Hcl | 52 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 22 |
| Baclofen | Baclofen | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 24 |
| Diazepam | Diazepam | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 12 |
| Estradiol | Estradiol | 44 | 16 |
| Ketoconazole | Ketoconazole | 44 | 22 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 37 |
| Fluconazole | Fluconazole | 42 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 12 |
| Spironolactone | Spironolactone | 37 | 12 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | 21 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Cephalexin | Cephalexin | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | 11 |
| Colchicine | Colchicine | 24 | 12 |
| Prolia | Denosumab | 24 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 17 |
| Atenolol | Atenolol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.18 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, EVENITY, FARXIGA, Kerendia, LOREEV XR, MOUNJARO, Omnipod, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, WATCHMAN Access System, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error